Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

172 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of A-101 for the Treatment of Seborrheic Keratosis

NCT02260180

Seborrheic Keratosis

COMPLETED PHASE2

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920

Seborrheic Keratosis (SK)

COMPLETED PHASE1/PHASE2

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

NCT02667236

Seborrheic Keratosis

COMPLETED PHASE3

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

NCT03148691

Seborrheic Keratosis

COMPLETED PHASE2

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

NCT03487588

Seborrheic Keratosis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.

Each subject will have 4 target lesions on the trunk/extremities.

A further objective is to evaluate the safety and efficacy of two concentrations of A-101 solution and its matching vehicle when applied to SK target lesions on the trunk/extremities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seborrheic Keratosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A-101 Vehicle

A-101 Vehicle (placebo) Topical Solution

Group Type PLACEBO_COMPARATOR

A-101 Vehicle

Intervention Type DRUG

Placebo control

A-101 (40) Topical Solution

A-101 (40) Topical Solution - high dose

Group Type ACTIVE_COMPARATOR

A-101 (40) Topical Solution

Intervention Type DRUG

A-101 (40) Topical Solution - high dose

A-101 (32.5) Topical Solution

A-101 (32.5) Topical Solution - low dose

Group Type ACTIVE_COMPARATOR

A-101 (32.5) Topical Solution

Intervention Type DRUG

A-101 (32.5) Topical Solution - low dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A-101 Vehicle

Placebo control

Intervention Type DRUG

A-101 (40) Topical Solution

A-101 (40) Topical Solution - high dose

Intervention Type DRUG

A-101 (32.5) Topical Solution

A-101 (32.5) Topical Solution - low dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is at least 18 years of age
2. Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis
3. Subject has 4 appropriate seborrheic keratosis target lesions, as defined below, on the trunk/extremities:

* Have a clinically typical appearance
* Be treatment naïve
* Have a Physician Lesion Assessment (PLA) of ≥2
* Have a longest axis that is ≥7mm and ≤15mm
* Have a longest dimension perpendicular to the longest axis that is ≥7mm and ≤15mm
* Have a thickness that is ≤2mm
* Be a discrete lesion
* Be, when centered in the area outlined by the provided 3cm diameter circular template, the only seborrheic keratosis lesion present
* Not be in an intertriginous fold
* Not be in an area where clothing, such as a bra, might cause physical irritation
* Not be pedunculated.
4. If the subject is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an active form of birth control for the duration of the study
5. Subject is non-pregnant and non-lactating
6. Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of any target lesion or which exposes the subject to an unacceptable risk by study participation
7. Subject is willing and able to follow all study instructions and to attend all study visits
8. Subject is able to comprehend and willing to sign an Informed Consent Form (ICF).

Exclusion Criteria

1. Subject has clinically atypical and/or rapidly growing seborrheic keratosis lesions
2. Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Leser-Trelat)
3. Subject has a current systemic malignancy
4. Subject has a history of keloid formation or hypertrophic scarring
5. Subject has used any of the following systemic therapies within the specified period prior to Visit 1:

* Retinoids; 180 days
* Glucocorticosteroids; 28 days
* Anti-metabolites (e.g., methotrexate); 28 days
6. Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to the target lesion, that in the investigator's opinion, interferes with the application of the study medication or the study assessments:

* LASER, light (e.g., intense pulsed light (IPL), photo-dynamic therapy (PDT)) or other energy based therapy; 180 days
* Retinoids; 90 days
* Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-fluorouracil, or ingenol mebutate; 60 days
* Glucocorticosteroids or antibiotics; 14 days
* Moisturizers/emollients, sunscreens; 12 hours
7. Subject currently has or has had any of the following within the specified period prior to Visit 1 on or in a proximity to the target lesion that, in the investigator's opinion, interferes with the application of the study medication or the study assessments:

* A cutaneous malignancy; 180 days
* Experienced a sunburn; 28 days
* A pre-malignancy (e.g., actinic keratosis); currently
* Body art (e.g., tattoos, piercing, etc.); currently
* Excessive tan; currently
8. Subject has a history of sensitivity to any of the ingredients in the study medications
9. Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations
10. Subject has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to Visit 1.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No